Faeth Therapeutics Q2 2026 net loss $16.0M; cash $186.4M; Phase 2 PIK-201 data expected year-end

Sensei Biotherapeutics, Inc.

2026-Q2 EPS reported -$53.50

Net loss of $16.0M ($2.84 per share) for Q2 2026, compared to $4.9M ($3.91 per share) in Q2 2025.
Cash, cash equivalents and marketable securities of $186.4M as of June 30, 2026, up from $21.2M at Dec 31, 2025, reflecting $200M PIPE financing.
Topline results from Phase 2 PIK-201 trial in endometrial cancer on track for year-end 2026.
First patient dosed in Phase 1b/2 PIK-101 trial in HR+ breast cancer in April 2026.
Company changed name to Faeth Therapeutics and began trading under ticker FTH on June 16, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.